24/7 Market News Snapshot 06 March, 2025 – PLUS THERAPEUTICS, Inc. Common Stock (NASDAQ:PSTV)

March 6, 2025

DENVER, Colo., 06 March, 2025 (247marketnews.com) – (NASDAQ:PSTV) are discussed in this article.
PLUS THERAPEUTICS, Inc. (PSTV) is experiencing a remarkable surge in the pre-market, with shares trading at $0.516, representing a notable increase of 47.43% from the previous day’s close of $0.350. This uptick signals robust investor confidence, evident from the trading volume which has reached 8.84 million shares. Analysts speculate that recent positive developments may have fueled this momentum, highlighting the company’s potential within the biotech sector.

In an exciting development, PLUS THERAPEUTICS has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for Rhenium (186Re) Obisbemeda, aimed at treating leptomeningeal metastases (LM) in patients with lung cancer. This significant designation underscores the company’s dedication to addressing critical needs for effective therapies in a patient population that currently faces limited treatment options.

Dr. Mike Rosol, Chief Development Officer at Plus Therapeutics, remarked on the importance of this achievement, calling it a major step forward in their commitment to develop essential therapies for those afflicted with lung cancer-related LM. The growing incidence of this condition amplifies the urgency for innovative solutions like Rhenium (186Re) Obisbemeda.

The Orphan Drug Designation confers several strategic advantages, including seven years of market exclusivity, clinical trial tax credits, and reduced regulatory fees. Coupled with the existing Fast Track designation, this positions PLUS THERAPEUTICS favorably in its mission to deliver advanced radiotherapeutic options to underserved patients. Following the successful completion of a Phase 1 trial that established the recommended Phase 2 dose, the company is poised to advance into subsequent clinical trial phases, exploring safety and efficacy further in collaboration with the FDA. PLUS THERAPEUTICS remains committed to innovating treatment pathways and enhancing quality of life for patients battling these complex challenges.

Related news for (PSTV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.